Hodgkin Lymphoma Involving the Extra-Axial CNS: An AHOD1331, PHL-C1 and PHL-C2 Report From the COG and EuroNet-PHL.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
26 Jul 2024
Historique:
accepted: 15 07 2024
received: 05 12 2023
revised: 20 06 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 26 7 2024
Statut: aheadofprint

Résumé

Hodgkin lymphoma (HL) involving the central nervous system (CNS) is exceedingly rare. Information regarding the presentation, management, treatment and outcome of patients with CNS HL is limited to case reports or small series. We describe 45 pediatric patients with 55 extra-axial CNS lesions at diagnosis with HL from a cohort of 4995 patients enrolled on Children's Oncology Group AHOD1331 and the European Network for Pediatric Hodgkin lymphoma (EuroNet-PHL) C1 and C2 trials (NCT02166463, NCT00433459 and NCT02684708, clinicaltrials.gov), with an overall incidence of 0.9%. 82.2% of patients had a single CNS lesion in the thoracic, lumbar or sacral spine. In the evaluated cohort, HL did not occur within the CNS parenchyma. Lesions extended into the extra-axial CNS space from adjacent soft tissue or bone and never directly infiltrated through the dura into the brain or spinal cord. Patients with CNS involvement had a 2-fold greater incidence of extranodal lesions (E-lesions) than previously reported cohorts without CNS involvement. 89.1% of CNS lesions demonstrated a complete metabolic response and >75% decrease in volume after two cycles of chemotherapy. Thirteen CNS lesions (23.6%) received irradiation, none were sites of disease relapse. Relapse occurred at the site of two lesions involving the CNS, both of which had an adequate interim response to chemotherapy. In summary, we present the largest reported cohort of systemic HL involving the CNS at diagnosis, demonstrating that these lesions originate from surrounding tissues, extend into the extra-axial CNS space, and respond similarly to other nodal and extranodal disease.

Identifiants

pubmed: 39058968
pii: 517178
doi: 10.1182/bloodadvances.2023012346
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02166463', 'NCT02684708', 'NCT00433459']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Reena Pabari (R)

The Hospital for Sick Children, Toronto, Ontario, Canada.

Kathleen M McCarten (KM)

IROCRI (Imaging and Radiation Oncology Core - Rhode Island/QARC, Lincoln, Rhode Island, United States.

Jamie E Flerlage (JE)

Golisano Children's Hospital, Rochester, New York, United States.

Hollie A Lai (HA)

Children's Health of Orange County, Orange, California, United States.

Christine Mauz-Koerholz (C)

Justus-Liebig-University of Giessen AND Martin Luther University of Halle-Wittenberg, Giessen, Germany.

Karin Dieckmann (K)

Medical University of Vienna, Vienna, Austria.

Monica Palese (M)

St Jude Children's Research Hospital, Memphis, Tennessee, United States.

Sue C Kaste (SC)

St. Jude Children's Research Hospital, Memphis, Tennessee, United States.

Sharon M Castellino (SM)

Childrens Hospital of Atlanta, Atlanta, Georgia, United States.

Kara M Kelly (KM)

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.

Dietrich Stoevesandt (D)

University Hospital Halle, Halle, Germany.

Lars Kurch (L)

University Hospital Leipzig, Leipzig, Germany.

Classifications MeSH